Fees Should Be A Last Resort For NICE Funding, Says UK Medtechs
Executive Summary
UK industry has given its rationale for opposing health technology assessment fees from NICE, but suggests that it might be prepared to discuss the general theme of NICE funding if the conditions were right.
You may also be interested in...
UK Looks To Model New Medtech Strategy On US Successes
The UK medtech industry sees the US very much as both a vital market and learning ground for future business and health-care system successes. That was the tone at recent meetings involving the UK industry association, which is ramping up its US-facing activity.
UK Accelerated Access Review Can Create A Post-Brexit 'Medtech Powerhouse'
Medical technology stakeholders in the UK will be poring over the detail of the much-anticipated Accelerated Access Review (AAR), the final report of which was released Oct. 24. The initial response from the industry has been positive.
UK Diagnostic Fret Over Loss of Support In Evidence Centers Restructure
Changes are afoot for the four UK Diagnostic Evidence Co-operatives that help generate clinical and cost-effectiveness data for innovative IVDs. Companies worry it could mean diagnostic industry needs get lost among broad medtech targets. Also, a roundup of the British In Vitro Diagnostics Association's key priorities, including the EU IVD Regulation, procurement issues, antimicrobial resistance, and of course, Brexit, highlighted at the group's 2016 annual meeting.